CMS Pharmacy Dashboard Insights

New CMS pharmacy dashboards include data sets from 2013 to 2017.

The Centers for Medicare & Medicaid Services (CMS) has released its latest “CMS Drug Spending Dashboards.” While the dashboards are interactive (you can look up specific drug data), we took a broader approach and downloaded and analyzed the source data.

The dashboard has the following data sets for 2013 through 2017:

  • Medicare Part D
  • Medicare Part B
  • Medicaid

For each drug and manufacturer, the data includes:

  • Total Spending
  • Total Dosage Units
  • Total Claims
  • Total Beneficiaries
  • Average Spending Per Dosage Unit (Weighted)
  • Average Spending Per Claim
  • Average Spending Per Beneficiary
  • Change in Average Spending Per Dosage Unit (2016-2017)
  • Annual Growth Rate in Average Spending Per Dosage Unit (2013-2017)

We specifically looked at Part D drugs with spending of over $1 billion. These drugs turned out to be focused on the following diseases:

Disease

Medicare D 2017 Spend

Claims

Type 1 and Type 2 Diabetes

$8,212,926,788

14,686,100

Blood Clots

$5,687,988,232

11,591,007

COPD

$5,547,814,048

12,289,852

Type 2 Diabetes

$3,817,588,316

5,785,217

Multiple Myeloma

$3,312,773,264

259,693

Psoriasis

$3,039,841,725

498,979

Hep C

$2,555,839,934

81,898

Nerve pain

$2,517,073,735

5,072,269

Multiple Sclerosis

$1,499,493,336

231,973

Hyperthyroidism

$1,436,678,980

985,214

Breast Cancer

$1,399,517,851

125,619

Leukemia

$1,368,727,295

131,205

Renal Failure

$1,316,266,396

892,182

Arthritis

$1,157,839,006

224,688

Dry Eye

$1,049,441,691

1,646,672

Grand Total

$43,919,810,595

54,502,568

Here are some of the critical trends we noted. First, the increase in the average Medicare costs for these drugs vastly outpaced inflation. 

Xarelto, for instance, a drug for treating blood clots, had an increase in market price for a monthly supply from $258.82 in 2013 to $461.40 in 2017. Xarelto also saw an increase in Medicare Part D payment rates for the same monthly supply, from $130.91 to $192.46 the same period. This yields increases in market cost and Medicare cost of 78 and 47 percent, respectively. Over the same period of time, according to the Bureau of Labor Statistics, wages only increased 12 percent. This means the cost of the drug was increasing 4 to 7 times faster than the inflation rate for salaries. 

We used salaries for two reasons in our analysis. First, because the cost of the drug is borne by people earning wages. Secondly, since the drug was fully developed, it made sense to us to use salaries since the main cost-driving production should be wages.

We noted that marketing appears to influence drug spending. Advertisements for drugs with over $1 billion in Medicare spending, including Xarelto (blood clots), Eliquis (blood clots), Harvoni (Hepatitis C) and Restasis (dry eye) seem to flood our media screens.      

As a final comment, it seems that many of the costly drugs relate to disease conditions heavily impacted by our own behavior.  One of the biggest causative factors in COPD, for instance, is smoking.  Similarly, the prevalence of type-2 diabetes correlates with America’s struggles with obesity.

As the last comment on something that may impact future drug development, we noted that actually curing a disease does not always help the drug companies’ bottom lines. Harvoni may have been a victim of its own success. Sales of this drug that treats hepatitis C fell from $4,399,701,570 in 2016 to $2,555,839,933 in 2017 as the patients that took the drug were cured.

We can’t imagine the pharmaceutical companies are not given pause by this.

Print Friendly, PDF & Email
Facebook
Twitter
LinkedIn

Timothy Powell, CPA, CHCP

Timothy Powell is a nationally recognized expert on regulatory matters, including the False Claims Act, Zone Program Integrity Contractor (ZPIC) audits, and U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG) compliance. He is a member of the RACmonitor editorial board and a national correspondent for Monitor Mondays.

Related Stories

Understanding the Wright Approach

Understanding the Wright Approach

Concern about hospitals sharing space has caused angst for several years. But as reiterated by Centers for Medicare & Medicaid Services (CMS) official David Wright,

Read More

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

Leveraging the CERT: A New Coding and Billing Risk Assessment Plan

Leveraging the CERT: A New Coding and Billing Risk Assessment Plan

Frank Cohen shows you how to leverage the Comprehensive Error Rate Testing Program (CERT) to create your own internal coding and billing risk assessment plan, including granular identification of risk areas and prioritizing audit tasks and functions resulting in decreased claim submission errors, reduced risk of audit-related damages, and a smoother, more efficient reimbursement process from Medicare.

April 9, 2024
2024 Observation Services Billing: How to Get It Right

2024 Observation Services Billing: How to Get It Right

Dr. Ronald Hirsch presents an essential “A to Z” review of Observation, including proper use for Medicare, Medicare Advantage, and commercial payers. He addresses the correct use of Observation in medical patients and surgical patients, and how to deal with the billing of unnecessary Observation services, professional fee billing, and more.

March 21, 2024
Top-10 Compliance Risk Areas for Hospitals & Physicians in 2024: Get Ahead of Federal Audit Targets

Top-10 Compliance Risk Areas for Hospitals & Physicians in 2024: Get Ahead of Federal Audit Targets

Explore the top-10 federal audit targets for 2024 in our webcast, “Top-10 Compliance Risk Areas for Hospitals & Physicians in 2024: Get Ahead of Federal Audit Targets,” featuring Certified Compliance Officer Michael G. Calahan, PA, MBA. Gain insights and best practices to proactively address risks, enhance compliance, and ensure financial well-being for your healthcare facility or practice. Join us for a comprehensive guide to successfully navigating the federal audit landscape.

February 22, 2024
Mastering Healthcare Refunds: Navigating Compliance with Confidence

Mastering Healthcare Refunds: Navigating Compliance with Confidence

Join healthcare attorney David Glaser, as he debunks refund myths, clarifies compliance essentials, and empowers healthcare professionals to safeguard facility finances. Uncover the secrets behind when to refund and why it matters. Don’t miss this crucial insight into strategic refund management.

February 29, 2024
2024 ICD-10-CM/PCS Coding Clinic Update Webcast Series

2024 ICD-10-CM/PCS Coding Clinic Update Webcast Series

HIM coding expert, Kay Piper, RHIA, CDIP, CCS, reviews the guidance and updates coders and CDIs on important information in each of the AHA’s 2024 ICD-10-CM/PCS Quarterly Coding Clinics in easy-to-access on-demand webcasts, available shortly after each official publication.

April 15, 2024

Trending News

Happy National Doctor’s Day! Learn how to get a complimentary webcast on ‘Decoding Social Admissions’ as a token of our heartfelt appreciation! Click here to learn more →

SPRING INTO SAVINGS! Get 21% OFF during our exclusive two-day sale starting 3/21/2024. Use SPRING24 at checkout to claim this offer. Click here to learn more →